MDXG - MiMedx Group Inc Debt to Book Capitalization Ratio

Graphic logo of MiMedx Group Inc (MDXG)

The MiMedx Group, Inc. (MDXG) price chart on the GURU.Markets platform reflects dynamics driven by scaling through the implementation of innovative tissue engineering methods, which ensure high returns with low costs. Business efficiency relies on outsourcing biomaterial collection and test oversight to external contractors, with the metric standing at 0.08. However, international conflicts are hindering growth by complicating raw material logistics and the protection of intellectual property rights.

MDXG (MiMedx Corp) Debt to Book Value history from 07/04/2022 to 10/28/2026
Core merchandise of MiMedx Group

This indicator reflects the proportion of borrowed funds within the overall structure of equity and debt capital, allowing for an assessment of financial stability and the business's degree of dependence on external financing. By analyzing the distribution of debt capital within the balance sheet capitalization, an investor can evaluate the ability of MiMedx Group, Inc. (MDXG) to maintain its R&D pipeline and the production of EpiFix biomaterials without risking an excessive debt burden on regenerative innovations.

Competitors of MiMedx Group, Inc. (MDXG)

Debts to Book Capitalization ASND (Ascendis Pharma A/S)|madrigalpharma.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Corcept Therapeutics Incorporated (CORT)|RYTM: Debt to Net Assets Ratio|AKRO (Akero Therapeutics Inc) - Debt to Book Capitalization Ratio|Metsera Therapeutics (MTSR) - Debt to Book Value|MLTX (MoonLake Immunotherapeutics) - Debts to Book Capitalization|Debts to Book Capitalization crinetics.com (CRNX)|NewAmsterdam Pharma Company N.V. (NAMS) - Debt to Book Value|Debt to Net Assets Ratio SLNO (Soleno Therapeutics Inc)|Amicus Pharma - Debt to Book Capitalization Ratio|Debt to Book Value 89bio Pharma ETNB|AGIO (Agios Pharmaceuticals) - Debts to Book Capitalization|structuretx.com (GPCR) - Debts to Book Value|RZLT - Debt to Book Value|Lexicon Pharmaceuticals Inc (LXRX) - Debt to Book Capital|MBX (MBX Bio) - Debts to Book Capitalization|Debts to Book Capitalization Altimmune Pharma|Debts to Book Capitalization Aardvark Therapeutics Inc (AARD)|Debt to Book Capitalization Ratio SGMT (sagimet.com)|BIOA: Debt to Book Capitalization Ratio|Biomea Fusion Inc - Debts to Book Value|QNCX - Debt to Book Capitalization Ratio|GUTS - Debt to Book Capitalization Ratio|vtvtherapeutics.com - Debts to Book Capitalization|ATPC (Agape ATP) - Debts to Net Assets|PLUR: Debt to Book Capitalization Ratio|Debts to Net Assets SYBX|Debt to Book Capitalization Ratio LPCN (Lipocine Corp)|Debt to Book Value MTNB (matinasbiopharma.com)|Spruce Biosciences, Inc. - Debt to Book Capitalization Ratio|Debt to Book Value galecto.com GLTO|Debts to Book Capitalization CTCX (Carmell)|LUMO: Debts to Net Assets|ONVO (Organovo Holdings Inc) - Debt to Book Capitalization Ratio|Radius Pharmaceuticals (RDUS) - Debt to Book Value